业界动态国内医卫资讯

STAT+:Ionis Pharmaceuticals 因该公司降甘油三酯药物的推广缓慢,股价暴跌

STAT News · 2026-11-10 08:50

摘要

Ionis Pharmaceuticals 周一市值蒸发超过 10 亿美元,此前该公司大幅下调了一款降甘油三酯药物的销售预期,而该生物技术公司及华尔街分析师认为这款药物有潜力成为重磅产品。该公司宣布,预计该药物 Tryngolza 到今年年底将实现 5000 万美元销售额,而 Ionis 此前预测为 1 亿至 1.1 亿美元。第三季度销售额为 900 万美元,远低于华尔街分析师该季度 2100 万美元的普遍预期。股市反应迅速。开盘时交易价格超过 39 美元的股票在数小时内跌破 28 美元,跌幅约为 25%。继续阅读 STAT+ 以了解完整报道……

English
STAT+: Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug

Ionis Pharmaceuticals lost more than $1 billion in market value on Monday after the company slashed sales projections for a triglyceride-lowering drug the biotech and Wall Street analysts believe is a potential blockbuster. The firm announced that it expects the drug, Tryngolza, to bring in $50 million in sales by the end of this year, compared to Ionis’ previous forecast of $100 to $110 million. Third quarter sales came in at $9 million, well below Wall Street consensus expectations of $21 million during the quarter. The stock reaction was swift. Shares that traded at more than $39 when the market opened within hours sank below $28, a drop of around 25%. Continue to STAT+ to read the full story…

内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界